Segment reporting

3 Months Ended

Mar. 31, 2022

Segment Reporting [Abstract]

Segment Reporting Disclosure

Segment reporting

The Company’s operating divisions are comprised of its U.S. dialysis and related lab services business (its U.S. dialysis business), its U.S. integrated kidney care business, its U.S. other ancillary services and its international operations (collectively, its ancillary services), as well as its corporate administrative support.

The Company’s separate operating segments include its U.S. dialysis and related lab services business, its U.S. integrated kidney care business, its U.S. other ancillary services, its kidney care operations in each foreign sovereign jurisdiction, its other health operations in each foreign sovereign jurisdiction, and its equity method investment in the Asia Pacific joint venture (APAC JV). The U.S. dialysis and related lab services business qualifies as a separately reportable segment, and all other operating segments have been combined and disclosed in the other segments category. See Note 25 to the Company's consolidated financial statements included in the 2021 10-K for further description of how the Company determines and measures results for its operating segments.

The following is a summary of segment net revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income before income taxes:

	Three months ended March 31,
	2022		2021
Segment revenues:
U.S. dialysis
Dialysis patient service revenues:
External sources	$	2,546,961	$	2,556,259
Intersegment revenues	22,159		26,944
U.S. dialysis patient service revenues	2,569,120		2,583,203
Other revenues:
External sources	5,966		6,616
Intersegment revenues	10		59
Total U.S. dialysis revenues	2,575,096		2,589,878
Other—Ancillary services
Dialysis patient service revenues	169,320		158,328
Other external sources	95,308		98,798
Intersegment revenues			4,293
Total ancillary services revenues	264,628		261,419
Total net segment revenues	2,839,724		2,851,297
Elimination of intersegment revenues	(22,169)		(31,296)
Consolidated revenues	$	2,817,555	$	2,820,001
Segment operating margin (loss):
U.S. dialysis	$	406,440	$	479,906
Other—Ancillary services	(32,305)		(11,860)
Total segment operating margin	374,135		468,046
Reconciliation of segment operating income to consolidated  income before income taxes:
Corporate administrative support	(35,827)		(25,444)
Consolidated operating income	338,308		442,602
Debt expense	(73,791)		(67,014)
Other (loss) income, net	(1,786)		1,168
Consolidated income before income taxes	$	262,731	$	376,756

Depreciation and amortization expense by reportable segment was as follows:

	Three months ended March 31,
	2022		2021
U.S. dialysis	$	162,019	$	155,946
Other—Ancillary services	10,925		9,755
	$	172,944	$	165,701

Expenditures for property and equipment by reportable segment were as follows:

	Three months ended March 31,
	2022		2021
U.S. dialysis	$	107,513	$	133,804
Other—Ancillary services	15,595		11,109
	$	123,108	$	144,913

 

A summary of assets by reportable segment were as follows:

	March 31, 2022		December 31, 2021
U.S. dialysis	$	15,227,817	$	15,375,000
Other—Ancillary services	1,859,193		1,746,488
Consolidated assets	$	17,087,010	$	17,121,488